LNAINasdaqPharmaceutical PreparationsFiscal year ends June 30
Lunai Bioworks Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Oct 13, 2026
$0.47−0.21 (-30.63%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Lunai Bioworks statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Lunai Bioworks | Industry median |
|---|---|---|
| Market Cap | $2.18M | $164.85M |
| Enterprise Value | $464.86K | $87.06M |
| PS Ratio | 41.90 | 3.60 |
Enterprise value
| Measure | Lunai Bioworks | Industry median |
|---|---|---|
| EV / Sales | 8.94 | 2.43 |
Income (trailing twelve months)
| Measure | Lunai Bioworks | Industry median |
|---|---|---|
| Revenue | $51.99K | $57.94M |
| Operating Income | -$8.70M | -$21.44M |
| Net Income | -$3.56M | -$22.46M |
| EBITDA | -$8.60M | -$16.91M |
Margins
| Measure | Lunai Bioworks | Industry median |
|---|---|---|
| Operating Margin | -16729.4% | -44.5% |
| Profit Margin | -6852.0% | -39.2% |
| EBITDA Margin | -16549.5% | -31.3% |
| FCF Margin | -10173.6% | -8.85% |
Returns
| Measure | Lunai Bioworks | Industry median |
|---|---|---|
| Return on Assets (ROA) | -39.2% | -41.0% |
Balance sheet
| Measure | Lunai Bioworks | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.71M | $62.42M |
| Net Cash (Debt) | $1.71M | $15.68M |
| Net Cash Per Share | $0.37 | $0.66 |
| Equity (Book Value) | -$9.02M | $48.79M |
| Book Value Per Share | -$1.96 | $1.36 |
| Tangible Book Value | -$16.40M | $23.06M |
| Working Capital | -$16.87M | $75.77M |
Financial position
| Measure | Lunai Bioworks | Industry median |
|---|---|---|
| Current Ratio | 0.11 | 3.30 |
| Quick Ratio | 0.09 | 2.39 |
| Interest Coverage | -37.00 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Lunai Bioworks | Industry median |
|---|---|---|
| Operating Cash Flow | -$5.29M | -$12.35M |
| Capital Expenditures | -$1.24K | -$1.06M |
| Free Cash Flow | -$5.29M | -$20.28M |
| FCF Per Share | -$1.15 | -$0.42 |
Efficiency
| Measure | Lunai Bioworks | Industry median |
|---|---|---|
| Asset Turnover | 0.01 | 0.38 |
| Revenue Per Employee | $4.33K | $398.96K |
| Profits Per Employee | -$296.87K | -$703.34K |
| Employee Count | 12 | 74 |
Dividends and yields
| Measure | Lunai Bioworks | Industry median |
|---|---|---|
| Earnings Yield | -163.5% | -22.7% |
| FCF Yield | -242.8% | -9.07% |
Shares
| Measure | Lunai Bioworks | Industry median |
|---|---|---|
| Shares Outstanding | 4,615,500 | 58,179,650 |
| Shares Change (QoQ) | -87.1% | 0.54% |
| Float | 3,888,840 | 49,173,100 |
| Shares Held by Insiders | 15.7% | 11.6% |
| Shares Held by Institutions | 3.44% | 59.4% |
Scores
| Measure | Lunai Bioworks | Industry median |
|---|---|---|
| Altman Z-Score | -77.23 | -0.24 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Lunai Bioworks's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.